Key result
A first-in-human combined transcatheter tricuspid valve implantation with a leadless VDD pacemaker via the left internal jugular approach was described.
Why the study?
Patients undergoing valve-in-valve tricuspid replacement often have CIED leads, presenting the challenge of extracting and replacing transvalvular leads versus entrapping them.
Case Report
This report describes the first-in-human combined transcatheter tricuspid valve implantation with a leadless VDD pacemaker via the left internal jugular approach.
Lead entrapment during tricuspid valve-in-valve replacement appears feasible in select cases; leaves open need for prospective safety data.
Percutaneous valve-in-valve tricuspid valve replacement has been an effective treatment for bioprosthetic tricuspid valve degeneration for over a decade.1 Cardiovascular implantable electronic device (CIED) indications in this patient group are common, and many patients being considered for valve-in-valve replacement have 1 or more endocardial ventricular leads. These present the operator with the choice to extract and replace transvalvular leads, or to entrap them between the valve stent and ring.
No takes yet. Share an insight, caveat, or question.
Hale et al. (2021) conducted a case report in Bioprosthetic tricuspid valve degeneration. Combined transcatheter tricuspid valve implantation with leadless VDD pacemaker via left internal jugular approach was evaluated. A first-in-human combined transcatheter tricuspid valve implantation with a leadless VDD pacemaker via the left internal jugular approach was described.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: